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group and diclofenac group were HKD10,211 (95% 
CI: HKD9,807–10,615) and HKD11,505 (95% CI:
HKD11,140–11,870), respectively. The results of the
decision tree analysis showed that the direct cost per
patient was HKD11,155 and HKD12,729 for the cele-
coxib and diclofenac groups, respectively. No threshold
value was identiﬁed by sensitivity analysis. CONCLU-
SION: Based on the analysis of the data obtained from a
large clinical trial, celecoxib was as safe as diclofenac with
omeprazole but appeared to cost less for the treatment of
arthritis in a group of high-risk Chinese patients.
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OBJECTIVE: Given the sensitivity of ﬁndings to the gas-
troprotective agent (GPA) rate assumption used in COX-
2 cost-effectiveness models, the purpose of this study is
to verify the GPA rate assumptions and to re-estimate
model outcomes from one published COX-2 cost-
effectiveness study using GPA rates from actual practice.
METHODS: Prescription and medical claims data from
a large preferred provider organization (PPO) located in
the Midwest were used to estimate GPA rates within 
three samples of adult patients new to non-selective non-
steroidal antiinﬂammatory drugs (NSAIDs) and COX-2
therapy: all new NSAID users, new NSAID users with a
diagnosis of arthritis, and a cohort matched on GI risk.
Members were continuously eligible over the study period
of January 1, 1999 through May 31, 2001. RESULTS:
Of the more than 319,000 members with at least 1 day
of eligibility, the number of members meeting inclusion
criteria in each of the three samples were 1,900 for new
NSAID users, 289 with a diagnosis of arthritis, and 1,386
in the matched cohort sample. GPA estimates for non-
selective NSAID and COX-2 users were consistent across
all 3 samples with COX-2 GPA rates of 22%, 21% and
20% and nonselective NSAID GPA rates of 15%, 15%,
and 18%, for new NSAID users, those with a diagnosis
of arthritis, and the matched cohort, respectively. Re-
estimation of the cost-effectiveness model using the most
conservative GPA rates increased the cost per year of life
saved for COX-2s from $18,614 to over $100,000.
CONCLUSIONS: Contrary to COX-2 cost-effectiveness
model assumptions, the rate of GPA use is positive and
marginally higher among COX-2 users than among non-
selective NSAID users. These ﬁndings call into question
the validity of assumptions regarding patterns of use
when made prior to a product’s use in the real world.
Given these ﬁndings, a re-evaluation of the cost-
effectiveness of COX-2 therapies should be considered.
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COST-EFFECTIVENESS OF RALOXIFENE FOR
THE PREVENTION OF OSTEOPOROTIC
FRACTURES IN AUSTRALIA
Davey PJ1, Lees M1, Graham-Clarke P2
1Medical Technology Assessment Group, Chatswood West,
NSW, Australia; 2Eli Lilly Australia Pty Ltd, West Ryde, NSW,
Australia
OBJECTIVES: In Australia, hormone replacement
therapy (HRT) is the standard therapy for reducing 
fracture risk in postmenopausal women with no previous
fracture. Therapies like bisphosphonates, calcitriol and
raloxifene are used in women with radiographically
deﬁned fracture resulting from minimal trauma. The
results of the Women’s Health Initiative study point to the
need, however, to assess the cost-effectiveness of newer
agents in preventing fracture in osteoporotic women
without prior fracture. This study aimed to assess the
cost-effectiveness of raloxifene in preventing osteoporotic
fractures in such a population. METHODS: A Markov
model was developed to compare raloxifene with HRT
and with alendronate in osteoporotic women with no
prior fracture. Relative efﬁcacy assumptions in the model
were based solely on the results of randomised controlled
trials (MORE, FIT-II, WHI), while transition probabili-
ties and downstream fracture effects were taken from a
range of literature. Primary outcomes included vertebral
fractures, non-vertebral fractures, breast cancer and car-
diovascular disease in a cohort with a low bone mineral
density and an average age of 65 years. The model 
contained 12 discrete states and yielded costs per 
quality-adjusted life-year (QALY). Limited memory was
incorporated into the model by separating each fracture
health state into two states, representing the ﬁrst and sub-
sequent years after fracture. The model ran for a 30-year
period, but therapy was assumed to continue for only 5
years, after which transition probabilities reverted to
values associated with no treatment. RESULTS: The
incremental cost per QALY gained with raloxifene treat-
ment compared with HRT in a population of osteo-
porotic women with no prior fracture was $14,506
(US$8,203). In the same population, raloxifene was
found to be more effective and less expensive than 
alendronate. Extensive sensitivity analyses indicated 
these results were robust. CONCLUSION: Raloxifene is
a cost-effective therapy to reduce fracture risk in post-
menopausal osteoporotic women without prior fracture.
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OBJECTIVES: This study investigates compliance with
hormone replacement therapy (HRT), bisphosphonate
